Compare Abeona Therapeutics Inc (ABEO) vs Mondaycom Ltd (MNDY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Mondaycom Ltd — how do they compare? Abeona Therapeutics Inc trades at $6.79 (market cap $373.32M), while Mondaycom Ltd trades at $81.3 (market cap $3.61B). The key difference: Mondaycom Ltd is far larger — about 9.7× Abeona Therapeutics Inc's market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, Mondaycom Ltd nearer its low. Which is the better fit depends on your goals.
| ABEO | MNDY | |
|---|---|---|
Market Cap | $373.32M | $3.61B |
Sector | Health | Technology |
52-Week High | $7.23 | $309.62 |
52-Week Low | $4.17 | $58.81 |
Enterprise Value | $228.22M | $2.57B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
Monday.com (MNDY) trades at $82.50, up 3.42% with strong technical momentum and bullish analyst sentiment. The stock shows robust fundamentals with consistent earnings beats (Q1 2026 EPS of $1.15 vs. $0.96 expected) and impressive 89% gross margins. Recent news highlights institutional interest despite some insider selling, while technical indicators suggest the stock is approaching resistance at $84.
The outlook remains positive with a $116.75 consensus price target (41% upside potential), though risks include high valuation multiples (P/E 36, EV/EBITDA 111) and projected negative cash flow in 2026. Revenue growth stability at 9%+ net margins supports the bullish case, but investors should monitor competitive pressures in the SaaS sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Mondaycom Ltd
Monday.com Ltd. is a cloud-based software company providing a Work OS (Operating System) that enables organizations to manage projects, processes, and daily work. The platform is highly customizable, enabling teams to build tailored applications and workflows for a range of use cases, from marketing and sales to software development and HR. monday.com serves clients across numerous industries, aiming to improve transparency, collaboration, and efficiency across the entire enterprise.
Read more on MNDY →
